In this section

Filter by year:

Events


Newsletters

Get in contact with us








Back

News & events


  • BioFocus extends collaboration with Amgen into 2012


    Fri 17 Dec 2010
    BioFocus announced today that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services. Under the terms of the extended agreement, BioFocus will receive €2.0 M ($2.6 M) in research fees for the first year. Additionally, BioFocus is eligible to receive payments of access fees and success-based milestones.

  • BioFocus extends collaboration with Chiesi


    Thu 14 Oct 2010
    BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, announced today that is has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached €2.5 million.

  • BioFocus and the National Cancer Institute sign compound management agreement


    Tue 12 Oct 2010
    BioFocus announced today that its Compound Focus subsidiary has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million (€3.7 M), with two one-year extension options.

  • BioFocus signs compound management agreement with eMolecules, Inc.


    Fri 08 Oct 2010
    BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services and eMolecules, Inc., the creators of the open-access chemical structure search engine, today announced that they have signed a compound management service agreement. Under the agreement eMolecules has selected Compound Focus, Inc., the BioFocus compound management operation located in South San Francisco, as its preferred partner for client compound order aggregation services.


  • BioFocus launches new compound libraries


    Fri 24 Sep 2010
    BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, today announced the launch of two new compound libraries, targeting Family C GPCR’s and protein-protein interactions.


  • Argenta expands collaboration with Genentech to include BioFocus


    Fri 10 Sep 2010
    Argenta, a service division of Galapagos NV, announced today it has signed a contract extension with Genentech, Inc., a member of the Roche Group. The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos’ other service division, BioFocus.



  • BioFocus and Usher III Initiative, Inc. announce collaboration


    Tue 07 Sep 2010
    BioFocus and the Usher III Initiative, Inc., a not-for-profit organization, announced today that they have embarked on a drug discovery project focused on Usher Syndrome Type III. Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.



  • BioFocus and University of Bristol enter drug discovery collaboration in chronic pain


    Fri 16 Jul 2010
    Saffron Walden and Bristol, UK; 16 July 2010 – BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total contract value for BioFocus could exceed €3.3 million in research fees over two years.



  • NIH extends agreement with BioFocus until end 2012


    Mon 12 Jul 2010
    Saffron Walden, UK; 12 July 2010 – BioFocus announced today that the U.S. National Institutes of Health (NIH) have extended their agreement for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. According to the terms of this agreement, BioFocus will be eligible to receive up to $8.6 million (€7.0 million) over the course of the two year extension.

  • BioFocus renouvelle son agrément CIR (Crédit Impôt Recherche)


    Tue 08 Jun 2010
    BioFocus, leader dans la fourniture de services de découverte de médicaments candidats, services qui vont du gène au candidat clinique, a annoncé aujourd'hui qu'il avait été notifié par le Ministère de l'Enseignement Supérieur et de la Recherche du renouvellement de son agrément CIR.


  • BioFocus renews C.I.R. (French Research Tax Credit) accreditation


    Tue 08 Jun 2010
    BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, today announced that it had been notified by the French Ministry of Higher Education and Research, that its CIR accreditation had been renewed.



  • BioFocus and CHDI Foundation, Inc. enter new five-year collaboration for Huntington’s disease therapeutics


    Thu 29 Apr 2010
    • Expands and extends collaboration initiated in 2005
    • Largest external collaboration to date for BioFocus
    • BioFocus eligible to receive US$41 million during five-year collaboration


  • BioFocus launches four compound libraries targeting kinases and protein-protein interactions


    Mon 12 Apr 2010
    BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, today announced the launch of four biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.

  • Today, Galapagos announced the purchase of Argenta Discovery 2009 Ltd.


    Tue 02 Feb 2010
    Today, Galapagos announced the purchase of Argenta Discovery 2009 Ltd., a privately held contract research drug discovery company with 140 employees. This company will operate under the name ‘Argenta’ as a Galapagos drug discovery service division. Together with BioFocus, the two companies will provide high quality services to the discovery research communities. The pairing-up of two profitable operations within the financially strong Galapagos Group will further maintain stability and hence credibility in the eyes of our client communities.

  • BioFocus achieves €1.6 M in payments


    Tue 12 Jan 2010
    BioFocus announced today that it has achieved success in its oncology target discovery collaboration with Ortho Biotech Oncology Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). The success of the program has resulted in €1.6 million in target acceptance payments.

  • TB Alliance and BioFocus sign compound management agreement


    Fri 08 Jan 2010
    BioFocus announced today that it has signed a three year compound management agreement with the Global Alliance for TB Drug Development (TB Alliance). Under this agreement BioFocus will manage TB Alliance’s chemical library collection. These services will be provided by BioFocus’ compound management facility in South San Francisco, USA.



Bookmark with:

What are these?


Print to HTML Print as PDF Send to a friend



BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.